Development of a potency assay for CD34(+) cell-based therapy

We have previously shown that intracardiac delivery of autologous CD34(+) cells after acute myocardial infarction (AMI) is safe and leads to long term improvement. We are now conducting a multicenter, randomized, controlled Phase I/IIb study in post-AMI to investigate the safety and efficacy of intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Aries, Anne, Vignon, Christine, Zanetti, Céline, Goubaud, Aurélien, Cormier, Arthur, Diederichs, Anne, Lahlil, Rachid, Hénon, Philippe, Garitaonandia, Ibon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640600/
https://www.ncbi.nlm.nih.gov/pubmed/37952030
http://dx.doi.org/10.1038/s41598-023-47079-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640600/
https://www.ncbi.nlm.nih.gov/pubmed/37952030
http://dx.doi.org/10.1038/s41598-023-47079-8

Ejemplares similares